QC
ONCY

Quadrature Capital’s Oncolytics Biotech ONCY Stock Holding History

Quadrature Capital’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-106,076
Closed -$146K – 1554
2025
Q3 		$146K Buy
+106,076
New +$119K ﹤0.01% 834

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Quadrature Capital's ONCY Position: Q4 2025 in Review

Quadrature Capital sold out of Oncolytics Biotech (ONCY) in Q4 2025, closing a stake of 106,076 shares — an estimated $146K sold.

Quadrature Capital first reported a position in ONCY in Q3 2025 and held it in 1 quarter. The position peaked at $146K in Q3 2025. 61 funds tracked by Wall St. Rank hold ONCY as of Q4 2025.

  • Quadrature Capital reported no remaining Oncolytics Biotech position as of Q4 2025 after selling out during the quarter.
  • Quadrature Capital sold 106,076 Oncolytics Biotech shares in Q4 2025, an estimated $146K.
  • Quadrature Capital first reported a position in Oncolytics Biotech in Q3 2025 and held it in 1 quarter.
  • Quadrature Capital's Oncolytics Biotech position peaked at $146K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.